	controls	Patients with OSA
		Before treatment	After treatment
Number of subjects	50	50	50
Age (years)	35.1±1.2	36.5±2.1	36.8±2.2
BMl (kg/m2)	24.1±2.3	27.5±2.1**	24.8±2.2♀
FPG (mmol/L)	4.75±1.12	5.09±1.23	4.93±1.22
TC (mmol/L)	4.54±1.55	4.82±1.12	4.59±1.33
LDL-C (mmol/L)	2.33±1.1 1	2.89±1.32	2.23±1.26
HDL-C (mmol/L)	l.58±0.35	1.17±0.57	1.32±0.61
TG(mmol/ L)	1.15±0.88	1.77±0.82*	l.37±0.95♀
HOMA-IR	2.33±1.33	4.45±1.26*	2.55±1.47 ♀♀
asprosin (ng/mL)	15.57±3.11l	6.64±1.79*	11.69±2.32
chemerin (ng/mL)	73.2±21.2	1 06.70± I 0.17*	84.01 ±12.22♀
ANGPTL4 (pg/mL)	36.88±5. 11	19.78±5.49	29.98±6.03♀
Ba-PWV(cm/s)	1211±218	1585±212*	1388±205
ABI	1.15±0.34	0.85±0.23*	0.98±0.13♀
AHI	3.4± 1.5	28.5±5.5**	1 l.3±3.3♀♀

* p < 0.05, * * p < 0.001, compared with control, ♀p < 0.05, compared with patients before treatment; ABI ankle-brachial index, AHI apnea-hypopnea index,ANGPTL4 angiopoietin-like 4, Ba-PWV brachial-ankle pulse wave velocity, FPG fasting glucose, HOMA-IR homeostasis model assessment of insulin resistance, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol,TG triglyceride
Table 1 : Clinical and biochemical characteristics in OSA patients as well as in control groups x̄±s

Tables at a glance

Figures at a glance